Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS)
Analysts from Guggenheim and J.P. Morgan reiterated Buy ratings on AbbVie (ABBV) with price targets of $288 and $285, respectively. Meanwhile, Bank of America Securities maintained a Sell rating on Alkermes (ALKS) with a $38 price target. ABBV closed at $272.42, ALKS at $40.11.
How this was made
The 30-second read
Why it matters
The new targets suggest modest directional moves for both stocks, with ABBV potentially gaining and ALKS facing pressure.
Market read
Analyst updates provide actionable signals for short‑term positioning in AbbVie and Alkermes.
What to watch
Upcoming earnings releases and pipeline news could outweigh the short‑term impact of these analyst updates.
Background
Analyst rating and price‑target revisions for two major healthcare companies were published, providing fresh guidance for traders.
Ticker impact
Guggenheim analyst reiterated a Buy rating on AbbVie with a new $288 price target, up from the prior close of $272.42.
likely upward pressure as the market prices in the higher target.
The fresh Buy rating and $288 target represent a ~5% upside from the last close, prompting traders to consider buying.
Bank of America analyst maintained a Sell rating on Alkermes with a $38 price target, below the last close of $40.11.
likely downward pressure as the market absorbs the lower target.
The Sell rating and $38 target suggest a modest downside (~5%) from the recent close, encouraging short or defensive positioning.
Market effects
Both updates affect the broader healthcare sector, reinforcing a slight tilt toward defensive pharma stocks.
U.S. market focus; no notable regional spillover.
Limited to investors tracking large-cap US pharma.
Counterpoint
Some investors may view the modest target changes as already priced in, limiting upside for ABBV and downside for ALKS.
Key entities
- AnalystVamil Divan
Guggenheim analyst who issued the AbbVie Buy rating.
- AnalystJason Gerberry
Bank of America analyst who maintained the Alkermes Sell rating.
